Eurofins Discovery Services North America, LLC

Eurofins Discovery Services North America, LLC is a foreign-owned, for-profit contract research organization headquartered in St. Charles, Missouri, with research facilities in St. Peters, Missouri and other locations across the United States. The company specializes in providing advanced scientific research and development services to support federal agencies' research initiatives, with particular expertise in receptor binding studies, toxicology testing, analytical chemistry, and non-clinical research methodologies. Through its federal contract portfolio, Eurofins has established itself as a trusted partner for agencies requiring specialized scientific testing and analysis capabilities across multiple disciplines.

Eurofins Discovery Services North America, LLC has provided a diverse range of goods and services through federal prime and subcontractor awards spanning multiple agencies and contract types. The company's primary service offerings include receptor profile screening and predictive toxicology services for the National Institute on Drug Abuse, confirmatory assays and safety pharmacology testing for the Environmental Protection Agency, in vitro screening services for food and chemical safety evaluation for the Food and Drug Administration, and preclinical models of infectious diseases for the National Institute of Allergy and Infectious Diseases. Additional services encompassed by the company's contract awards include quantitative bioanalysis, dose response analyses, lead identification and synthesis services, and non-clinical laboratory support. Contract values have ranged from approximately $8,000 to over $6.1 million, with firm-fixed-price and cost-plus-fixed-fee structures employed across various delivery orders and task orders. Notably, none of the identified awards to Eurofins Discovery Services North America, LLC utilized small business set-aside designations, reflecting the specialized and non-competitive nature of much of the contracted work. The company's federal customer base has included the National Institute on Drug Abuse, Environmental Protection Agency, Food and Drug Administration, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences, National Heart Lung and Blood Institute, Department of Veterans Affairs, and various other components of the National Institutes of Health.

Eurofins Discovery Services North America, LLC currently holds four indefinite delivery vehicle contracts with federal agencies representing a combined ceiling value exceeding $84.9 million. The largest of these IDVs is a $50 million single-award contract with the National Institute of Allergy and Infectious Diseases for interventional agents safety and pharmacokinetic services, awarded in September 2025 with performance through September 2032. The company also holds a $20 million single-award IDV with the Food and Drug Administration for research and development services and studies through September 2028, under which the company has executed delivery orders for in vitro screening services and non-clinical laboratory support. A $9.7 million single-award IDV with the Environmental Protection Agency's Office of Research and Development for in vitro and target-based assays extends through December 2026 and has supported multiple delivery orders for confirmatory assays, safety pharmacology, and chemical mechanism of action research. Additionally, Eurofins holds a $5 million single-award IDV designated for small business with the National Institute on Drug Abuse for receptor binding and predictive toxicology services through September 2028. Under the NIAID's Nonclinical Services for Development of Interventional Agents parent master IDIQ vehicle, Eurofins has executed multiple delivery orders including the substantial $6.1 million preclinical models contract. These IDVs collectively demonstrate Eurofins' capacity to deliver sophisticated scientific services across multiple federal agencies and research domains on an indefinite, ongoing basis.